Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights

Lindblom, Julius; Mohan, Chandra; Parodis, Ioannis

doi:10.1097/bor.0000000000000862

Cited by 22 publications

(24 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that the usCD163 level and usCD163/creatinine ratio were also correlated with the SLEDAI-2K score and anti-ds DNA Ab level. Serum-soluble CD163 ( 29 ), monocyte chemoattractant protein-1 (MCP-1), neutrophil gelatinase-associated lipocalin (NGAL), TNF-like weak inducer of apoptosis (TWEAK), and vascular cell adhesion molecule-1 (VCAM) are new biomarkers of SLE disease activity ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Urine Soluble CD163 Is a Promising Biomarker for the Diagnosis and Evaluation of Lupus Nephritis

et al. 2022

View full text Add to dashboard Cite

IntroductionUrine-soluble CD163 (usCD163) is released from alternatively activated macrophages involved in the resolution of inflammation in glomeruli and plays an important role in glomerulonephritis. This study explored the role of usCD163 in patients with systemic lupus erythematosus (SLE).Materials and MethodsusCD163 concentrations were measured cross-sectionally in 261 SLE patients in Taiwan. Clinical and laboratory data were collected, and SLE disease activity scores were calculated to assess the correlation with usCD163.ResultsSLE patients with high usCD163 levels tended to be younger, with a higher hospital admission rate, higher prednisolone dose, lower estimated glomerular filtration rate, higher urine protein creatinine ratio (UPCR), more pyuria and hematuria, higher levels of inflammatory markers, higher rates of anemia, neutropenia, and lymphopenia, lower complement 3 (C3) levels, higher anti-double-stranded DNA antibody (anti-dsDNA Ab) levels, and higher disease activity scores (p < 0.05). usCD163 levels were significantly higher in patients with active lupus nephritis (LN) than in those with extrarenal or inactive SLE and correlated with UPCR, disease activity, and anti-dsDNA Ab levels. SLE patients with high usCD163 levels tended to have a higher chronic kidney disease stage.Discussion and conclusionThe usCD163 level correlates with the severity of LN and disease activity in renal SLE.

show abstract

Section: Discussionmentioning

confidence: 99%

Urine Soluble CD163 Is a Promising Biomarker for the Diagnosis and Evaluation of Lupus Nephritis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Therefore, data reported in this study should be considered specific to the used measurement method and sample matrix, i.e., EDTA-plasma. An improvement of harmonization in the measurement of circulating calprotectin could highlight the real value of this marker in COVID-19 as well as in other inflammatory diseases, such as autoimmune diseases [ 30 , 31 ] and atherosclerosis-based cardiovascular diseases [ 32 , 33 , 34 ]. Another point that should be addressed to improve the adoption of calprotectin in routine analyses is related to the timing of calprotectin increase before the worsening of diseases.…”

Section: Discussionmentioning

confidence: 99%

Calprotectin Levels and Neutrophil Count Are Prognostic Markers of Mortality in COVID-19 Patients

et al. 2022

View full text Add to dashboard Cite

Inflammation plays a crucial role in worsening coronavirus disease (COVID-19). Calprotectin is a pro-inflammatory molecule produced by monocytes and neutrophilic granulocytes. The aim of the study was to evaluate both the prognostic role of circulating calprotectin levels and neutrophil count toward fatal outcome in COVID-19 patients. We retrospectively collected and analyzed data on 195 COVID-19 adult patients, 156 hospitalized in the infectious disease unit and 39 in the intensive care unit (ICU). Calprotectin levels and neutrophil counts measured at the first hospitalization day were higher in the patients with a fatal outcome than in surviving ones. The association of high calprotectin levels and neutrophil count to patient death remain significant by logistic regression, independent of patient age. ROC curves analysis for calprotectin levels and neutrophil count revealed a good discriminatory power toward survival (area under the curve of 0.759 and 0.843, respectively) and identified the best cut-off (1.66 mg/L and 16.39 × 103/µL, respectively). Kaplan–Meier analysis confirmed the prognostic role of high calprotectin levels and neutrophil count in death prediction. In conclusion, this study highlights that calprotectin levels together with neutrophil count should be considered as biomarkers of mortality in COVID-19 patients.

show abstract

“…However, the disease remission rate is still not where we want to see it, although the overall rate of SLE patients who have achieved and maintained remission status has improved considerably over recent decades, and further evidence is required to better characterize the pathogenesis and features of SLE, especially in patients in the Asia Pacific region [ 16 , 17 ]. Discovery of new biomarkers of SLE has always been positive, as it can provide better comprehension of SLE pathogenesis and could also be a potential treatment target, for example, CD163, which has been a hot topic lately [ 18 , 19 ]. Nevertheless, this seems to provide limited value to our clinical decisions and treatment, although it would indeed add more benefit in choosing study topics and developing novel treatment targets.…”

Section: Discussionmentioning

confidence: 99%

Efficiency of Disease and Disease Activity Diagnosis Models of Systemic Lupus Erythematosus Based on Protein Array Analysis

Zhao

Liu

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

Background. Systemic lupus erythematosus (SLE) has become increasingly common in the clinic and requires complicated evidence of both clinical manifestations and laboratory examinations. Additionally, the assessment and monitoring of lupus disease activity are challenging. We hope to find efficient biomarkers and establish diagnostic models of SLE. Materials and Methods. We detected and quantified 40 proteins using a quantitative protein array of 76 SLE patients and 21 healthy controls, and differentially expressed proteins were screened out by volcano plot. Logistic regression analysis was used to recognize biomarkers that could be enrolled in the disease diagnosis model and disease activity diagnosis model, and a receiver operating characteristic (ROC) curve was drawn to evaluate the efficiency of the model. A nomogram was depicted for convenient and visualized application of our models in the clinic. Decision curves and clinical impact curves were also plotted to validate our models. Results. The protein levels of TNF RII, BLC, TNF RI, MIP-1b, eotaxin, MIG, MCSF, IL-8, MCP-1, and IL-10 showed significant differences between patients with SLE and healthy controls. TNF RII and MIP-1b were included in the SLE diagnosis model with logistic regression analysis, and the value of the area under the ROC curve (AUC) was 0.914 (95% confidence interval (CI), 0.859-0.969). TNF RII, BLC, and MIP-1b were enrolled in the disease activity diagnosis model, and the AUC value was 0.823 (95% CI 0.729-0.916). Both of the models that we established showed high efficiency. Additionally, the three protein biomarkers contained in the disease activity distinguish model provided additional benefit to conventional biomarkers in predicting active lupus. Conclusions. The disease diagnosis model and disease activity diagnosis model that we developed based on protein array chip results showed high efficiency in differentiating patients with SLE from healthy controls and recognizing SLE patients with high disease activity, and they have also been validated. This implied that they might greatly benefit clinical decisions and the treatment of SLE.

show abstract

Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights

Cited by 22 publications

References 93 publications

Urine Soluble CD163 Is a Promising Biomarker for the Diagnosis and Evaluation of Lupus Nephritis

Urine Soluble CD163 Is a Promising Biomarker for the Diagnosis and Evaluation of Lupus Nephritis

Calprotectin Levels and Neutrophil Count Are Prognostic Markers of Mortality in COVID-19 Patients

Efficiency of Disease and Disease Activity Diagnosis Models of Systemic Lupus Erythematosus Based on Protein Array Analysis

Contact Info

Product

Resources

About